The therapy has shown efficacy in various types of solid tumors, and talimogene laherparepvec, genetically modified herpes simplex viruses expressing granulocyte-macrophage colony stimulating factor (GM-CSF), was approved by the FDA in October 2015 for the treatment of melanoma.84 The gene discussed is CSF2; the disease is melanoma.